Drugs / BFH772
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00987870 | Sep 2009 → Feb 2010 | arthritic joint disease, psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01449591 | Sep 2011 → Feb 2012 | rosacea | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BFH772 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01449591 ↗ |
| Known as | BFH-722 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4080062 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL4080062 ↗ |
| Modality | Small molecule | — CHEMBL4080062 ↗ |
| Route | Topical | “Multiple Topical Administrations of BFH772” NCT00987870 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL4080062 ↗ |